AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Virtual Clinical Trials Market Report 2024-2029 - Breaking Down Barriers in Women's Health Clinical Studies
16 sept. 2024 08h37 HE
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trials Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Virtual Clinical Trials...
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
16 sept. 2024 08h30 HE
|
Adaptive Research Inc
BAMF Health and Adaptive Research announced a strategic partnership to increase physician participation and patient enrollment in clinical trials.
Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials
16 sept. 2024 08h00 HE
|
Science 37, Inc.
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global...
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
16 sept. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),...
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
16 sept. 2024 06h30 HE
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
13 sept. 2024 06h55 HE
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
Avance Clinical Joins the Australian Clinical Trials Roadshow, Sharing Cost and Time Benefits for Early-Phase US Biotechs
13 sept. 2024 05h23 HE
|
Avance Clinical
Avance Clinical will represent the CRO sector at the Australian Clinical Trials Roadshow to share the unparalleled time, cost and quality opportunities.
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)